{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:42:23Z","timestamp":1793900543096,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103221"],"award-info":[{"award-number":["82103221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072714"],"award-info":[{"award-number":["82072714"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M683094"],"award-info":[{"award-number":["2020M683094"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the program of Guangdong Provincial Clinical Research Center for Digestive Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circular RNAs have been reported to play essential roles in the tumorigenesis and progression of various cancers. However, the biological processes and mechanisms involved in hepatocellular carcinoma (HCC) remain unclear. Initial RNA-sequencing data and qRT-PCR results in our cohort showed that hsa_circ_0072309 (also called circLIFR) was markedly downregulated in HCC tissues. Kaplan\u2013Meier analysis indicated that higher levels of circLIFR in HCC patients correlated with favorable overall survival and recurrence-free survival rates. Both in vitro and in vivo experiments indicated that circLIFR inhibited the proliferation and invasion abilities of HCC cells. We therefore conducted related experiments to explore the mechanism of circLIFR in HCC. Fluorescence in situ hybridization results revealed that circLIFR was mainly located in the cytoplasm, and RNA immunoprecipitation assays indicated that circLIFR was significantly enriched by Ago2 protein. These results suggested that circLIFR may function as a sponge of miRNAs to regulate HCC progression. We further conducted bioinformatics prediction as well as dual-luciferase reporter assays, and the results of which showed that circLIFR could sponge miR-624-5p to stabilize glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) expression. Loss and gain of function experiments demonstrated that regulation of the expression of miR-624-5p or GSK-3\u03b2 markedly affected HCC progression induced by circLIFR. Importantly, we also proved that circLIFR could facilitate the degradation of \u03b2-catenin and prevent its translocation to the nucleus in HCC cells. Overall, our study demonstrated that circLIFR acts as a tumor suppressor in HCC by regulating miR-624-5p and inactivating the GSK-3\u03b2\/\u03b2-catenin signaling pathway.<\/jats:p>","DOI":"10.1038\/s41419-022-04887-6","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T12:15:47Z","timestamp":1652789747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3\u03b2\/\u03b2-catenin signaling pathway"],"prefix":"10.1038","volume":"13","author":[{"given":"Lei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-7682","authenticated-orcid":false,"given":"Changzhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"4887_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4887_CR2","first-page":"506","volume":"16","author":"ND Ferrante","year":"2020","unstructured":"Ferrante ND, Pillai A, Singal AG. Update on the diagnosis and treatment of hepatocellular carcinoma. Gastroenterol Hepatol. 2020;16:506\u201316.","journal-title":"Gastroenterol Hepatol"},{"key":"4887_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","volume":"154","author":"XF Xu","year":"2019","unstructured":"Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH, et al. Risk Factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154:209\u201317.","journal-title":"JAMA Surg"},{"key":"4887_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers13112744","volume":"13","author":"M Papatsirou","year":"2021","unstructured":"Papatsirou M, Artemaki PI, Karousi P, Scorilas A, Kontos CK. Circular RNAs: emerging regulators of the major signaling pathways involved in cancer progression. Cancers. 2021;13:11.","journal-title":"Cancers."},{"key":"4887_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-021-01145-8","volume":"14","author":"H Shen","year":"2021","unstructured":"Shen H, Liu B, Xu J, Zhang B, Wang Y, Shi L, et al. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. J Hematol Oncol. 2021;14:134.","journal-title":"J Hematol Oncol"},{"key":"4887_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.21037\/atm.2020.02.134","volume":"8","author":"P Wang","year":"2020","unstructured":"Wang P, Xu LL, Zheng XB, Hu YT, Zhang JF, Ren SS, et al. Correlation between the expressions of circular RNAs in peripheral venous blood and clinicopathological features in hepatocellular carcinoma. Ann Transl Med. 2020;8:338.","journal-title":"Ann Transl Med"},{"key":"4887_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.29270","volume":"66","author":"D Han","year":"2017","unstructured":"Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66:1151\u201364.","journal-title":"Hepatology."},{"key":"4887_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04464-3","volume":"13","author":"D Li","year":"2021","unstructured":"Li D, Zhang J, Yang J, Wang J, Zhang R, Li J, et al. CircMTO1 suppresses hepatocellular carcinoma progression via the miR-541-5p\/ZIC1 axis by regulating Wnt\/\u03b2-catenin signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis. 2021;13:12.","journal-title":"Cell Death Dis"},{"key":"4887_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/1878-0261.12603","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Dai C, Yu X, Yin XB, Zhou F. Circ-TCF4.85 silencing inhibits cancer progression through microRNA-486-5p-targeted inhibition of ABCF2 in hepatocellular carcinoma. Mol Oncol. 2020;14:447\u201361.","journal-title":"Mol Oncol"},{"key":"4887_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020;5:298.","journal-title":"Signal Transduct Target Ther"},{"key":"4887_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/CMAR.S186857","volume":"11","author":"L Yan","year":"2019","unstructured":"Yan L, Zheng M, Wang H. Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492. Cancer Manag Res. 2019;11:1033\u201341.","journal-title":"Cancer Manag Res"},{"key":"4887_CR12","first-page":"5","volume":"23","author":"X Guo","year":"2021","unstructured":"Guo X, Qin M, Hong H, Xue X, Fang J, Jiang L, et al. Circular RNA hsa_circ_0072309 inhibits the proliferation, invasion and migration of gastric cancer cells via inhibition of PI3K\/AKT signaling by activating PPAR\u03b3\/PTEN signaling. Mol Med Rep. 2021;23:5.","journal-title":"Mol Med Rep"},{"key":"4887_CR13","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1080\/21691401.2019.1657873","volume":"47","author":"T Chen","year":"2019","unstructured":"Chen T, Shao S, Li W, Liu Y, Cao Y. The circular RNA hsa-circ-0072309 plays anti-tumour roles by sponging miR-100 through the deactivation of PI3K\/AKT and mTOR pathways in the renal carcinoma cell lines. Artif Cells Nanomed Biotechnol. 2019;47:3638\u201348.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4887_CR14","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/cas.13028","volume":"107","author":"T Domoto","year":"2016","unstructured":"Domoto T, Pyko IV, Furuta T, Miyashita K, Uehara M, Shimasaki T, et al. Glycogen synthase kinase-3\u03b2 is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107:1363\u201372.","journal-title":"Cancer Sci"},{"key":"4887_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/cas.14861","volume":"112","author":"Q Li","year":"2021","unstructured":"Li Q, Sun M, Wang M, Feng M, Yang F, Li L, et al. Dysregulation of Wnt\/\u03b2-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci 2021;112:1695\u2013706.","journal-title":"Cancer Sci"},{"key":"4887_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/hepr.12256","volume":"44","author":"KT Huang","year":"2014","unstructured":"Huang KT, Huang YH, Li P, He B, Chen ZK, Yu X, et al. Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy. Hepatol Res. 2014;44:1142\u201350.","journal-title":"Hepatol Res"},{"key":"4887_CR17","doi-asserted-by":"publisher","first-page":"e105624","DOI":"10.1371\/journal.pone.0105624","volume":"9","author":"G Qiao","year":"2014","unstructured":"Qiao G, Le Y, Li J, Wang L, Shen F. Glycogen synthase kinase-3\u03b2 is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma. PLoS ONE. 2014;9:e105624.","journal-title":"PLoS ONE"},{"key":"4887_CR18","doi-asserted-by":"publisher","first-page":"9539","DOI":"10.2147\/OTT.S229507","volume":"12","author":"H Chen","year":"2019","unstructured":"Chen H, Liu S, Li M, Huang P, Li X. circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt\/\u03b2-catenin pathway in hepatocellular carcinoma. Onco Targets Ther. 2019;12:9539\u201349.","journal-title":"Onco Targets Ther"},{"key":"4887_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03276-1","volume":"11","author":"G Huang","year":"2020","unstructured":"Huang G, Liang M, Liu H, Huang J, Li P, Wang C, et al. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p\/RTKN2 axis and activating Wnt\/\u03b2-catenin pathway. Cell Death Dis. 2020;11:1065.","journal-title":"Cell Death Dis"},{"key":"4887_CR20","doi-asserted-by":"publisher","first-page":"D239","DOI":"10.1093\/nar\/gkx1141","volume":"46","author":"D Karagkouni","year":"2018","unstructured":"Karagkouni D, Paraskevopoulou MD, Chatzopoulos S, Vlachos IS, Tastsoglou S, Kanellos I, et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 2018;46:D239\u201345.","journal-title":"Nucleic Acids Res"},{"key":"4887_CR21","doi-asserted-by":"publisher","first-page":"e05005","DOI":"10.7554\/eLife.05005","volume":"4","author":"V Agarwal","year":"2015","unstructured":"Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005","journal-title":"Elife"},{"key":"4887_CR22","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92\u20137.","journal-title":"Nucleic Acids Res"},{"key":"4887_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/hep4.1029","volume":"1","author":"E Indersie","year":"2017","unstructured":"Indersie E, Lesjean S, Hooks KB, Sagliocco F, Ernault T, Cairo S, et al. MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting \u03b2-catenin and Wnt signaling. Hepatol Commun. 2017;1:168\u201383.","journal-title":"Hepatol Commun"},{"key":"4887_CR24","doi-asserted-by":"publisher","first-page":"116660","DOI":"10.1016\/j.lfs.2019.116660","volume":"231","author":"L Qiu","year":"2019","unstructured":"Qiu L, Xu H, Ji M, Shang D, Lu Z, Wu Y, et al. Circular RNAs in hepatocellular carcinoma: Biomarkers, functions and mechanisms. Life Sci. 2019;231:116660.","journal-title":"Life Sci"},{"key":"4887_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01360-4","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xiao X, Wei W, Huang C, Wang M, Wang L, et al. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutS\u03b1\/ATM-p73 axis in bladder cancer. Mol Cancer. 2021;20:70.","journal-title":"Mol Cancer"},{"key":"4887_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/hepr.12571","volume":"46","author":"Y Wang","year":"2016","unstructured":"Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma. Hepatol Res. 2016;46:89\u201399.","journal-title":"Hepatol Res"},{"key":"4887_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s13046-019-1491-6","volume":"38","author":"Y Luo","year":"2019","unstructured":"Luo Y, Liu W, Tang P, Jiang D, Gu C, Huang Y, et al. miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells. J Exp Clin Cancer Res. 2019;38:488.","journal-title":"J Exp Clin Cancer Res"},{"key":"4887_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01346-0","volume":"20","author":"X Liu","year":"2020","unstructured":"Liu X, Yang L, Jiang D, Lu W, Zhang Y. Circ-DENND4C up-regulates TCF4 expression to modulate hepatocellular carcinoma cell proliferation and apoptosis via activating Wnt\/\u03b2-catenin signal pathway. Cancer Cell Int. 2020;20:295.","journal-title":"Cancer Cell Int"},{"key":"4887_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01281-8","volume":"19","author":"J Xu","year":"2020","unstructured":"Xu J, Wan Z, Tang M, Lin Z, Jiang S, Ji L, et al. N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating \u03b2-catenin signaling. Mol Cancer. 2020;19:163.","journal-title":"Mol Cancer"},{"key":"4887_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/atm-20-2081","volume":"9","author":"W Tan","year":"2021","unstructured":"Tan W, Lin Z, Chen X, Li W, Zhu S, Wei Y, et al. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med. 2021;9:38.","journal-title":"Ann Transl Med"},{"key":"4887_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2018.12.047","volume":"40","author":"W Tan","year":"2019","unstructured":"Tan W, Luo X, Li W, Zhong J, Cao J, Zhu S, et al. TNF-\u03b1 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2019;40:446\u201356.","journal-title":"EBioMedicine."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04887-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:52:13Z","timestamp":1669301533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04887-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["4887"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04887-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"2 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All sample tissue collections were approved by the Ethics Committee of the Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Animal experiments were approved by the Bioethics Committee of Sun Yat-Sen University and were performed according to the National Institutes of Health guidelines (approval number SYSU-IACUC-2021-B0113).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"464"}}